U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H34O5
Molecular Weight 390.5131
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEVASTATIN

SMILES

CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12

InChI

InChIKey=AJLFOPYRIVGYMJ-INTXDZFKSA-N
InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H34O5
Molecular Weight 390.5131
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27581384 | https://www.ncbi.nlm.nih.gov/pubmed/3981532

Mevastatin (compactin or ML-236B) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This drug induces apoptosis and arrest of cancer cells in G1 phase. Therapeutic effects of mevastatin on serum level of lipoproteins and unbiquinone-10 in patients with familial hypercholesterolemia were investigated. However, that study was discontinued. In addition, mevastatin was investigated for the treatment of melanoma. It was suggested, that mevastatin was unlikely to prevent melanoma at standard doses. However, higher doses could have a role to play in adjuvant therapy by inhibiting growth and invasion of melanoma cells. Also was revealed, that mevastatin increased histone deacetylase inhibitor, LBH589-induced cell death in triple-negative breast cancer (TNBC) cells.

Originator

Sources: Tetrahedron Volume42 Issue18 Pages 4909-51https://www.ncbi.nlm.nih.gov/pubmed/1010803

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P04035
Gene ID: 3156.0
Gene Symbol: HMGCR
Target Organism: Homo sapiens (Human)
1.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma.
2006-07-01
Statins inhibit growth of human endometrial stromal cells independently of cholesterol availability.
2006-07
Involvement of Rho signaling in PAR2-mediated regulation of neutrophil adhesion to lung epithelial cells.
2006-04-24
HMG-CoA reductase inhibitors induce apoptosis in pericytes.
2006-03
Biosynthesis of mono- and sesquiterpenes in strawberry fruits and foliage: 2H labeling studies.
2006-02-22
Activators of the energy sensing kinase AMPK inhibit random cell movement and chemotaxis in U937 cells.
2006-02
Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway.
2006-01-15
HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways.
2006-01
Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro.
2006
Statins prevent beta-amyloid inhibition of sympathetic alpha7-nAChR-mediated nitrergic neurogenic dilation in porcine basilar arteries.
2005-12
Cholesterol biosynthesis and the pro-apoptotic effects of the p75 nerve growth factor receptor in PC12 pheochromocytoma cells.
2005-10-03
Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil.
2005-09-09
Fast analysis of pravastatin in production media.
2005-08-05
Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells.
2005-08-02
Genomic effect of vitamin 'C' and statins within human mononuclear cells involved in atherogenic process.
2005-08
In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis.
2005-07
Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway.
2005-07
Induction of macrophage elastase (MMP-12) gene expression by statins.
2005-07
Cholesterol modulation of the expression of mitochondrial aconitase in human prostatic carcinoma cells.
2005-06-30
Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin.
2005-06-28
Chlamydophila pneumoniae induces expression of toll-like receptor 4 and release of TNF-alpha and MIP-2 via an NF-kappaB pathway in rat type II pneumocytes.
2005-06-03
4,8-Dimethyldecanal, the aggregation pheromone of Tribolium castaneum, is biosynthesized through the fatty acid pathway.
2005-06
FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells.
2005-06
Novel and simple high-performance liquid chromatographic method for determination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity.
2005-05-25
HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma.
2005-05-09
Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-delta.
2005-05
Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells.
2005-04-15
Induction of de novo volatile terpene biosynthesis via cytosolic and plastidial pathways by methyl jasmonate in foliage of Vitis vinifera L.
2005-04-06
Disruption of lipid rafts causes apoptotic cell death in HaCaT keratinocytes.
2005-04
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
2005-04
Progesterone-receptor antagonists and statins decrease de novo cholesterol synthesis and increase apoptosis in rat and human periovulatory granulosa cells in vitro.
2005-03
Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
2005-02-15
Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
2005-01-01
Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK.
2005-01
High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line.
2005-01
Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia.
2004-11-12
Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis.
2004-10
Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3beta and transcription factor beta-catenin.
2004-09
Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins.
2004-08-17
Chronic mevastatin modulates receptor-dependent vascular contraction in eNOS-deficient mice.
2004-08
Mevastatin-induced apoptosis and growth suppression in U266 myeloma cells.
2004-07-28
Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis.
2004-07-16
[In vitro effects of mevastatin on the proliferation and apoptosis in human multiple myeloma cell line U266].
2004-06
Isolation and characterization of a novel trans-factor for luteinizing hormone receptor mRNA from ovary.
2004-04-09
Statins inhibit osteoblast migration by inhibiting Rac-Akt signaling.
2004-03-12
De novo biosynthesis and radiolabeling of mammalian digitalis-like factors.
2004-03
Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
2004-02
[Mevastatin induced apoptosis in U266 human myeloma cell line].
2004
Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient.
2002-10-27
Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity.
1976-12-31
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:52:54 GMT 2025
Edited
by admin
on Wed Apr 02 07:52:54 GMT 2025
Record UNII
1UQM1K0W9X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEVASTATIN
INN   MART.   MI  
INN  
Official Name English
MEVASTATIN [MI]
Preferred Name English
L637312
Code English
ML236B lactone
Code English
NSC-281245
Code English
(1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-(2-((2R,4R)-TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHYL (S)-2-METHYLBUTYRATE
Common Name English
NSC-759322
Code English
NSC281245
Code English
mevastatin [INN]
Common Name English
L-637312
Code English
MEVASTATIN [USP-RS]
Common Name English
CS-500
Code English
ML-236B lactone
Code English
(+)-Compactin
Common Name English
CS500
Code English
MEVASTATIN [MART.]
Common Name English
LOVASTATIN IMPURITY A [EP IMPURITY]
Common Name English
COMPACTIN
Common Name English
MEVASTATIN [JAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1655
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
Code System Code Type Description
WIKIPEDIA
MEVASTATIN
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
RS_ITEM_NUM
1443216
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
MERCK INDEX
m7513
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY Merck Index
NSC
759322
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
EVMPD
SUB08927MIG
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
NCI_THESAURUS
C96285
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
MESH
C012258
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
INN
4943
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
EPA CompTox
DTXSID4040684
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
ChEMBL
CHEMBL54440
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
CAS
73573-88-3
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
SMS_ID
100000081177
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
DRUG BANK
DB06693
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
PUBCHEM
64715
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
FDA UNII
1UQM1K0W9X
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
CHEBI
34848
Created by admin on Wed Apr 02 07:52:54 GMT 2025 , Edited by admin on Wed Apr 02 07:52:54 GMT 2025
PRIMARY
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY